Аннотация:
The aim of the study was to perform a complex pharmacoepidemiological (ATC/DDD method of the WHO) and pharmacoeconomic analysis of the influence of APDs on a budget of in-patient psychiatric facilities. The present study was based on the WHO methodology on drug statistics (ATC/DDD-analysis) and budget impact analysis. The authors developed the tool of cost calculation via the cost of 1 DDD, which can be used at planning hospital budget on drugs. Costs for drugs were estimated from the national hospitals' sources (2015). Initially, 8.5[%] of patients were treated with atypical long-acting injectable fluphenazine (FLU LAI) and 13[%] with oral chlorpromazine (CHL). The results of the study showed that FLU LAI had lower a cost of therapy, calculated per DDD dose, and was more effective in preventing relapse in schizophrenic patients in comparison with CHL (OR 0.31, CI 95[%] 0.11-0.88). If the proportion of patients, receiving FLU LAI increases by 1[%] while the proportion of patients, receiving CH
Maksimkina E. A. Elena Anatolyevna 1961-
Vas`kova L. B. Larisa Borisovna 1964-
Musina N. Z. Nuriya Zagitovna 1979-
Tyapkina M. V. Marina Vladimirovna 1987-
Максимкина Е. А. Елена Анатольевна 1961-
Васькова Л. Б. Лариса Борисовна 1964-
Мусина Н. З. Нурия Загитовна 1979-
Тяпкина М. В. Марина Владимировна 1987-
Budget impact analysis of antipsychotic drugs in the hospital treatment of schizophrenia
Текст визуальный непосредственный
Periodico Tche Quimica
Vol.16, Issue32 P. 509-515
2019
Статья
Budget impact analysis Consumption DDD analysis Pharmacoeconomics Schizophrenia
The aim of the study was to perform a complex pharmacoepidemiological (ATC/DDD method of the WHO) and pharmacoeconomic analysis of the influence of APDs on a budget of in-patient psychiatric facilities. The present study was based on the WHO methodology on drug statistics (ATC/DDD-analysis) and budget impact analysis. The authors developed the tool of cost calculation via the cost of 1 DDD, which can be used at planning hospital budget on drugs. Costs for drugs were estimated from the national hospitals' sources (2015). Initially, 8.5[%] of patients were treated with atypical long-acting injectable fluphenazine (FLU LAI) and 13[%] with oral chlorpromazine (CHL). The results of the study showed that FLU LAI had lower a cost of therapy, calculated per DDD dose, and was more effective in preventing relapse in schizophrenic patients in comparison with CHL (OR 0.31, CI 95[%] 0.11-0.88). If the proportion of patients, receiving FLU LAI increases by 1[%] while the proportion of patients, receiving CH